Sensei biotherapeutics reports favorable preliminary dose expansion data for solnerstotug in pd-(l)1 resistant tumors

– initial clinical activity in a pd-(l)1 resistant population, with an orr almost three times higher than historical pd-(l)1 rechallenge response rates, with data still maturing –

SNSE Ratings Summary

SNSE Quant Ranking